On November 17, 2023, WuXi XDC Cayman Inc. (WuXi XDC) was successfully listed on the Main Board of the Stock Exchange of Hong Kong, raising approximately HK$3,676 million (US$470 million) from its IPO, or approximately HK$4,070.7 million (US$520.4 million) if the underwriters fully exercise their over-allotment option, making it the third largest IPO and the largest biotech IPO in Hong Kong this year to date. Wilson Sonsini Goodrich & Rosati acted as issuer’s U.S. counsel in the IPO and Hong Kong listing. The firm also acted as the U.S. and Hong Kong counsel of WuXi AppTec Co., Ltd., a controlling shareholder of WuXi XDC (WuXi AppTec), in connection with this transaction. 

WuXi XDC is a leading contract research, development, and manufacturing organization focused on the global antibody-drug conjugate and broader bioconjugate market. WuXi XDC offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. 

The Wilson Sonsini team that represented WuXi XDC and WuXi AppTec in the transactions included:

Corporate
Weiheng Chen
Winfield Lau
Ke Li
Haoqian Chen
Rujin Ruan
Giselle Ma
Yan Liang

Tax
Myra A. Sutanto Shen
Anthony Yanez

For more information, please see WuXi Biologics’ press release.